Cytek Biosciences, Inc.

For the period ended Jun 30, 2026. Filed Aug 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 5, 2026

CTKB$5.79-1.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders' Equity

Common stock · Additional paid-in capital · Accumulateddeficit · Accumulated other comprehensive income (loss) · Totalstockholders’ equity
(In thousands, except share data) · Shares · Amount
Balances at December 31, 2025	128,550,136	$129		$441,107		$(101,738)		$2,241	$341,739
Shares issued in connection with employee stock plans	647,968	1	20		—	—	21
Shares of Common Stock withheld related to net share settlement	(55,517)	(1)	(238)		—	—	(239)
Stock-based compensation	—	—	4,861		—	—	4,861
Unrealized loss on marketable securities	—	—	—		—	(201)	(201)
Foreign currency translation adjustment, net of tax	—	—	—		—	328	328
Net loss	—	—		—		(18,866)		—	(18,866)
Balances at March 31, 2026	129,142,587	$129		$445,750		$(120,604)		$2,369	$327,644
Shares issued in connection with employee stock plans	655,680	1	90		—	—	91
Proceeds from Employee Stock Purchase Plan	236,193	—	851		—	—	851
Shares of Common Stock withheld related to net share settlement	(51,707)	—	(184)		—	—	(184)
Stock-based compensation	—	—	5,339		—	—	5,339
Unrealized loss on marketable securities	—	—	—		—	(147)	(147)
Foreign currency translation adjustment, net of tax	—	—	—		—	517	517
Net loss	—	—	—		(12,158)	—	(12,158)
Balances at June 30, 2026	129,982,753	$130		$451,846		$(132,761)		$2,739	$321,954

Common stock · Additional paid-in capital · Accumulateddeficit · Accumulated other comprehensive income (loss) · Totalstockholders’ equity
(In thousands, except share data) · Shares · Amount
Balances at December 31, 2024	129,205,901		$129			$430,791				$(35,199)		$16	$395,737
Shares issued in connection with employee stock plans	500,830	1		38	—		—		39
Shares of Common Stock withheld related to net share settlement	(29,006)	—		(129)	—		—		(129)
Repurchase of shares	(2,078,583)	(2)		(10,625)	—		—		(10,627)
Stock-based compensation	—	—		6,630	—		—		6,630
Unrealized loss on marketable securities	—	—		—	—		(65)		(65)
Foreign currency translation adjustment, net of tax	—	—		—	—		(560)		(560)
Net loss	—	—		—	(11,402)		—		(11,402)
Balances at March 31, 2025	127,599,142		$128			$426,705				$(46,601)		$(609)	$379,623
Shares issued in connection with employee stock plans	545,702		1		65			—			—	66
Proceeds from Employee Stock Purchase Plan	292,212		—		703			—			—	703
Shares of Common Stock withheld related to net share settlement	(37,938)		(1)		(102)			—			—	(103)
Repurchase of shares	(1,214,005)		(1)		(4,509)			—			—	(4,510)
Stock-based compensation	—		—		6,791			—			—	6,791
Unrealized loss on marketable securities	—		—		—			—			(33)	(33)
Foreign currency translation adjustment, net of tax	—		—		—			—			603	603
Net loss	—		—		—			(5,583)			—	(5,583)
Balances at June 30, 2025	127,185,113		$127			$429,652				$(52,184)		$(38)	$377,557

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.